The mixed Phase 2 asthma data (statistically significant FEV1 but missed primary endpoint) creates uncertainty. The upcoming COPD data readout later this month is the next key catalyst. Traders should watch for the COPD results and any FDA meeting announcements to gauge the viability of the Phase 3 program.
Price Chart
Executive Summary
Connect Biopharma reported positive preliminary Phase 2 topline data for rademikibart as an add-on treatment for acute asthma exacerbations. The drug showed a statistically significant improvement in lung function (FEV1) at Day 7 (p=0.023) and a 66% reduction in treatment failure rate, though the primary endpoint missed statistical significance (p=0.153) due to a lower-than-expected event rate. The company plans to report COPD data later this month and engage with the FDA on a Phase 3 program, providing a near-term catalyst but leaving regulatory path uncertainty unresolved.
Key Facts
- Rademikibart showed a statistically significant 130mL greater improvement in post-bronchodilator FEV1 at Day 7 vs placebo (p=0.023).
- Treatment failure rate was reduced by 66% vs placebo (2.5% vs 7.4%), but missed statistical significance (p=0.153) due to a lower-than-projected overall event rate.
- The study enrolled 160 patients (79 rademikibart, 81 placebo) with type 2 inflammation and eosinophil count ≥300 cells/µL.
- Rademikibart was well-tolerated with a safety profile comparable to placebo; 1 SAE in the drug arm vs 3 in placebo.
- Company expects to report Phase 2 COPD data later this month and plans to meet with FDA to align on a Phase 3 program.
Financial Impact
No financial data reported; clinical-stage biotech with no revenue. Potential milestone payments up to ~$99M from Simcere license in Greater China.
Risk Factors
- Primary endpoint missed statistical significance, raising regulatory risk for Phase 3 design.
- Low event rate in the study may complicate powering of future trials.
- No revenue or near-term commercialization path; dependent on partnership milestones and financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001835268-26-000034 |
| Exhibit: exhibit991.htm | 0001835268-26-000034 |
| Exhibit: exhibit992.htm | 0001835268-26-000034 |
| Document: 0001835268-26-000034-index-headers.html | 0001835268-26-000034 |
| Document: 0001835268-26-000034-index.html | 0001835268-26-000034 |
| Document: 0001835268-26-000034.txt | 0001835268-26-000034 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | SC 13G | $0.9450 $0.9090 | ▼ −3.81% | ▼ −2.83% | $0.8430 (−10.79%) |
Sep 30, 2026 27d ago | 8-K | $1.10 $0.9450 | ▼ −14.09% | ▼ −16.00% | $0.8430 (−23.36%) |
Sep 30, 2026 27d ago | Press Release | $1.10 $0.9447 | ▼ −14.12% | ▼ −16.03% | $0.8430 (−23.36%) |
Sep 15, 2026 6w ago | 8-K | $1.17 $1.28 | ▲ +9.40% | ▲ +8.58% | $0.8430 (−27.95%) |
May 12, 2026 24w ago | 8-K | $2.68 $2.38 | ▼ −11.19% | ▼ −11.27% | $0.8430 (−68.54%) |
May 12, 2026 24w ago | Press Release | $2.68 $2.38 | ▲ +11.19% | ▲ +11.27% | $0.8430 (+68.54%) |
Apr 23, 2026 26w ago | 8-K | $2.52 $2.53 | ▲ +0.40% | ▼ −1.08% | $0.8430 (−66.55%) |
Mar 31, 2026 30w ago | 8-K | $2.72 $2.78 | ▲ +2.21% | ▼ −1.56% | $0.8430 (−69.01%) |
Mar 30, 2026 30w ago | Press Release | $2.90 $2.82 | ▼ −2.76% | ▼ −7.06% | $0.8430 (−70.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers